Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Tax Provisions (2020 - 2025)

Collegium Pharmaceutical has reported Tax Provisions over the past 6 years, most recently at $12.1 million for Q4 2025.

  • Quarterly results put Tax Provisions at $12.1 million for Q4 2025, up 155.08% from a year ago — trailing twelve months through Dec 2025 was $29.7 million (up 1.26% YoY), and the annual figure for FY2025 was $29.7 million, up 1.26%.
  • Tax Provisions for Q4 2025 was $12.1 million at Collegium Pharmaceutical, up from $11.9 million in the prior quarter.
  • Over the last five years, Tax Provisions for COLL hit a ceiling of $14.8 million in Q4 2023 and a floor of -$61.9 million in Q2 2021.
  • Median Tax Provisions over the past 5 years was $2.9 million (2021), compared with a mean of $398450.0.
  • Biggest five-year swings in Tax Provisions: crashed 25243.09% in 2021 and later surged 6900.76% in 2024.
  • Collegium Pharmaceutical's Tax Provisions stood at -$13.8 million in 2021, then skyrocketed by 95.72% to -$592000.0 in 2022, then soared by 2594.93% to $14.8 million in 2023, then tumbled by 67.96% to $4.7 million in 2024, then skyrocketed by 155.08% to $12.1 million in 2025.
  • The last three reported values for Tax Provisions were $12.1 million (Q4 2025), $11.9 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.